A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM)

Sponsor
Eli Lilly and Company
Study ID
NCT04823208
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
20 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

  • LY3437943 — DRUG
    Administered SC
  • Placebo — DRUG
    Administered SC

Study Details

The main purpose of this study is to learn about the side effects of LY3437943 when given to Japanese participants with type 2 diabetes mellitus. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. Each enrolled participant will receive injections of LY3437943 or placebo given just under the skin. For each participant, the study will last up to 5 months, inclusive of screening and will include 16 visits to the study center.

Key Dates

Start date
May 24, 2021
Status verified
Aug 2022
Primary completion
Jun 23, 2022
Completion
Jun 23, 2022

Study Design

Enrollment
64 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: LY3437943
    LY3437943 administered subcutaneously (SC)
  • Placebo Comparator: Placebo
    Placebo administered SC

Primary Outcome Measure

Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration [ Time Frame: Baseline through Day 106 ]

Related Studies